RCRamazan Cetinkaya

Ramazan Cetinkaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ramazan Cetinkaya has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    REVISION OF MEDICAL EDUCATION PROGRAM OUTCOMES ON THE UCEP 2020: EXPERIENCE OF AKDENIZ UNIVERSITY FACULTY OF MEDICINE

    by Erol Gürpinar, Yeşim ŞENOL, Aslı BOSTANCI, Neval Boztuğ, Levent Sarikçioğlu, Mustafa Kemal Ali̇moğlu, Ramazan Çeti̇nkaya, Murat Turhan, Özlenen Özkan

    Giriş: Ulusal çekirdek Eğitim programı 2020 tarihinde yenilenmiş (UÇEP-2020) ve Yüksek Öğretim Kurumu tarafından kabul edilerek ülkemizdeki tüm tıp fakültelerine 2021-2022 eğitim döneminden itibaren uygulanması kararı verilmiştir. Çalışmanın amacı UÇEP-2020 doğrultusunda Akdeniz Üniversitesi Tıp Fakültesi, program çıktılarının revizyon sürecinin tanıtılmasıdır. Yöntem: UÇEP 2020’nin yayınlanması ile birlikte, Akdeniz Üniversitesi Tıp Fakültesi Program çalışmalarının güncellenmesi işlemi 2020-2021 eğitim döneminde iç paydaşların geniş katılımı ile başlatılmıştır Bulgular: UÇEP 20202’ye göre programın yeterlikleri ve kazanımları yeniden düzenlenmiş, dönem, ders kurulu/staj ve derslerin çıktıları gözden geçirildi. Bazı eksik yeterlikler ve kazanımlar Fakülte yeterlik listesine eklendi. Hazırlanan yeterlik listeleri soru bankasına girildi. Tartışma: Akdeniz Üniversitesi tıp fakültesi mezuniyet çıktıları iç paydaşların geniş katılımı ile gözden geçirilmiştir. Bu sürecin eğitimde hesap verilebilirlik ve kalite güvencesi sürecine katkı sağlayacağı düşünülmektedir. Deneyimlerimiz, benzer süreci kurumlarında başlatmak isteyen diğer tıp fakülteleri için yol gösterici olabilir.


  • Open Access

    The Frequency of Fabry Disease in Hemodialysis Patients in The Western Mediterranean Region of Turkey

    by Elif Nazlı SERİN, Ünal Ataş, Ramazan Çeti̇nkaya, Funda Sari

    Amaç: Bu çalışmanın amacı, Batı Akdeniz bölgesinde hemodiyaliz uygulanan ancak böbrek yetmezliği etiyolojisi bilinmeyen veya başka nedenlere bağlanan hastaları belirlemek ve bu hastalardaki Fabry mutasyonunun prevalansını saptamaktır. Ayrıca çalışmamızda mutasyon saptanan olguların aile bireylerinde de tarama yapmayı amaçladık. Yöntemler: Türkiye'de Batı Akdeniz bölgesinde 11 farklı hemodiyaliz merkezinde hemodiyaliz tedavisi gören 18 yaş üstü 664 hasta tarandı. Erkek hastalarda ilk olarak Alfa-galaktosidaz A enzim seviyeleri test edildi ve alfa-galaktosidaz A seviyeleri < 3,3 nmol/mL/saat olan hastalarda GLA gen dizi analizi yapıldı. Kadınlarda ise GLA gen dizi analizi doğrudan yapıldı. Bulgular: Toplam 664 hasta [313 (%47.1) erkek ve 351 (%52.9) kadın] tarandı. Fabry mutasyonu sekiz kadın hastada ve bir erkek hastada pozitifti. Sonuç: Araştırmamızda hemodiyaliz tedavisi alan hastalarda Fabry hastalığı prevalansı %1,35 olarak belirlendi. Fabry hastalığının etiyolojisinde etkili olan mutasyonların yalancı alel olup olmadığı konusundaki çelişkileri ortadan kaldırmak için yeni araştırmaların yapılması, daha geniş hasta popülasyonunda prospektif tarama programlarının yapılması, genetik danışmanlık ve koruyucu hekimlik hizmetlerinin yaygınlaştırılması gerekmektedir. Aims: The aim of the present study was to identify patients with chronic kidney disease of unknown etiology or of other detected etiology among those who were undergoing hemodialysis in the Western Mediterranean region and to detect the prevalence of Fabry mutation in these patients. In addition, we aimed to screen the family members of the cases with mutations in our study. Methods: A total of 664 patients over the age of 18 who received hemodialysis treatment in 11 different hemodialysis centers in the Western Mediterranean region of Turkey were screened. Alpha-galactosidase A enzyme levels were first tested in male patients, and for patients with alpha-galactosidase A levels < 3.3 nmol/mL/h, GLA gene sequence analysis was performed. GLA gene sequence analysis was performed directly in female patients. Results: In total 664 patients [313 (47.1%) male and 351 (52.9%) female] have been scanned. Fabry mutation was positive in eight female patients and one male patient. Conclusion: According to the output of the research, the prevalence of Fabry disease among the patients who receive hemodialysis treatment determined 1.35%. In order to eliminate the conflicts upon whether the mutations which is effective on the etiology of Fabry disease are pseudo alleles it is required that new researches should be done, prospective scanning programs in a wider patient population and genetic consultancy and preventive medicine services should become more prevalent.


  • A case of cyclic hemoperitoneum in a hemodialysis patient: Encapsulated peritoneal sclerosis complicated by endometriosis and fungal peritonitis

    by Fatih Yılmaz, Feyza Bora, Ramazan Çetinkaya, Mustafa Tekinalp Gelen, Gültekin Süleymanlar, Fevzi Ersoy

    Encapsulated peritoneal sclerosis (EPS) is a rare, but frequently fatal, long‐term complication of peritoneal dialysis. Endometriosis is a common gynecological problem but hemoperitoneum due to endometriosis has been reported to be extremely rare in hemodialysis (HD) patients. A 25‐year‐old female HD patient was admitted to our clinic with nausea, vomiting, abdominal pain, and weight loss for last 3 months. Candida tropicalis and Candida glabrata were isolated in the fungal cultures from peritoneal fluid. Her abdominal computerized tomography scan has shown irregular peritoneal calcifications, diffuse peritoneal thickening, dilatation of the small bowel loops, and cocoon formation which all were typical for EPS. Hemoperitoneum was reported to recur for four times with intervals suggesting menstrual cycles. Her peritoneal biopsy, along with the signs of EPS, has also revealed the presence of endometriosis. The patient died with symptoms of septic shock in the first year of EPS diagnosis.


  • Open Access

    Comparison of Clinical Outcomes in Hepatitis B Virus–Positive and –Negative Renal Transplant Recipients

    by Vural Taner Yilmaz, Ramazan Cetinkaya, Halide Akbas, Sebahat Ozdem, Burak Veli Ulger, Halil Erbis, Mehmet Bakirtas, İbRahim Aliosmanoglu, Gultekin Suleymanlar, Dilek Colak, et al.

    Our aim was to compare the short- and long-term clinical outcomes of hepatitis B surface antigen–positive (HbsAg+) renal transplant recipients with HbsAg− recipients. A total of 204 patients who underwent renal transplantation in our center between 2001 and 2014 were included in the study. The patients were divided into 2 groups. Group 1 was the HbsAg− group (n = 136), and group 2 was the HbsAg+ group (n = 68). There was no significant difference between the groups in terms of lymphocyte crossmatches, numbers of mismatches, immunosuppressive treatment protocols, and induction treatments. In the HbsAg+ group, 51 patients were hepatitis B virus DNA+, 64 patients were HbeAg−, and 4 patients were HbeAg+. A total of 57 patients (83.8%) were treated with lamivudine, 4 patients (5.9%) with entecavir, and 7 patients (10.3%) with tenofovir for hepatitis B infection. Graft and patient survival rates, graft functions, acute hepatitis rates, acute rejection rates, and other clinical outcomes of the groups were compared. Demographic data and immunologic risk profiles of the groups were similar. Acute rejection rates, graft survival rates, and patient survival rates were similar. Acute hepatitis rates, glomerular filtration rates on the last controls, and delayed graft function rates were higher in group 2, whereas chronic allograft dysfunction and new-onset diabetes mellitus after transplantation rates were similar between the groups. Our study revealed that graft and patient survival, and acute rejection rates were similar between HbsAg+ and HbsAg− recipients, whereas acute hepatitis rate was higher in HbsAg+ recipients.

  • Open Access

    FP876THREE YEARS RESULTS OF RENAL TRANSPLANTATION IN SENSITIZED END STAGE RENAL DISEASE PATIENTS

    by Huseyin Kocak, Ibrahim Aliosmanoglu, Halil Erbis, Sadi Koksoy, Vural Taner Yilmaz, Gultekin Suleymanlar, Ramazan Cetinkaya, Fevzi Ersoy, Ayhan Dinckan

    Introduction and Aims: Preformed HLA-Antibody due to various reasons is major barrier for renal transplantation.Different combination and doses of immunoglobuline, plasma Exchange, rituximab were introduced to those patients for desensitization. Herein we report three years results of immunologically high risk 15 renal transplant patients desensitized by combination of immunoglobuline, plasma exchange and rituximab

  • Evaluation of neopterin levels in patients undergoing hemodialysis

    by Ali Asci, Terken Baydar, Ramazan Cetinkaya, Anil Dolgun, Gonul Sahin

    Neopterin is a diagnostic or a prognostic biomarker for several pathologies including renal diseases. However, the association between neopterin status and causative main reasons such as diabetes and hypertension for renal disease remains unclear. The aim of the study was to evaluate neopterin levels in diabetes and hypertension patients treated with/without hemodialysis. According to primary renal disorders, the patients undergoing hemodialysis were classified into 4 groups as diabetic nephropathy, hypertensive nephropathy, reflux nephropathy or interstitial nephritis, and others. The controls consisted of healthy subjects, hypertensive subjects, and diabetic individuals without any renal disorder. In the study, both urinary and serum neopterin levels were measured using high performance liquid chromatography and enzyme‐linked immunosorbant assay in patients undergoing regular hemodialysis therapy (n=71). The effects of the duration of hemodialysis and treatment of erythropoietin and/or iron on neopterin levels were also evaluated. Neopterin levels were found to be higher in hemodialysis patients than in the healthy controls (P<0.05). A significant difference in neopterin levels was also found between diabetic control patients and diabetic nephropathy patients (P<0.05). A similar significant difference was detected in neopterin levels between hypertensive patients with/without nephropathy (P<0.05). Neopterin may be an early critical marker for progression of nephropathy in diabetic and hypertensive patients in early stages.